Key points

  • Multiple sclerosis (MS) is a chronic degenerative disease of the CNS characterized by demyelination and axonal degeneration in the brain and spinal cord, which are caused by an immune-mediated inflammatory process.
  • Impaired vision (due to retrobulbar neuritis) is usually the first manifestation of MS; other neurological deficits appear as the disease progresses. The most common clinical course is characterized by exacerbations followed by periods of complete or incomplete remission.

Epidemiology

  • Sex: ♀ > ♂ (3:1)
  • Age of onset: 20–40 years of age
  • Ethnicity: ↑ prevalence among the white and black population
  • Prevalence: 50-300 per 100 000 people (greater among people who live further from the equator)

Etiology

The etiology of multiple sclerosis is unclear; it is believed to develop in genetically predisposed people who have been exposed to certain environmental factors.

  • Environmental risk factors
    • Low vitamin D levels (insufficient intake, decreased exposure to UV radiation)

Pathophysiology

L39372.jpg

  • Pathophysiology of MS is characterized by autoimmune inflammation, demyelination, and axonal degeneration.
  • Most commonly accepted theory: Activation of autoreactive T-lymphocytes → inflammatory processes → focal demyelination with partial preservation of axons (acute plaques) → loss of axons and atrophy of oligodendrocytes (chronic plaques) → gliosis → inadequate remyelination
  • B-lymphocyte dysfunction: The following suggests that B-lymphocytes play a role in the pathogenesis of MS, although the exact mechanism of their involvement is unclear.
    • Anti-CD20 agents (ocrelizumab, ofatumumab, rituximab) are effective in preventing exacerbations.
    • Presence of tertiary lymphoid organs in the meninges of individuals with secondary progressive MS
    • Intrathecal synthesis of IgG (oligoclonal bands; see “Diagnostics” section for more information)
  • Progressive phenotypes (forms) of MS are characterized by
    • Chronic inflammation that occurs with an intact blood-brain barrier and is driven by immune cells compartmentalized in the leptomeninges and perivascular spaces
    • Accelerated compared to relapsing-remitting phenotype brain atrophy

Clinical features

Pasted image 20230923161821.png

  • Optic neuritis
    • Most often the earliest manifestation
    • Typically unilateral
    • Can be painful
    • Impaired vision and color blindness
    • Relative afferent pupillary defect (Marcus Gunn pupil)
  • Internuclear ophthalmoplegia (INO) as a result of a lesion in the medial longitudinal fasciculus (MLF)
    • Ipsilateral medial rectus weakness but an intact convergence reflex
    • Disconjugate, lateral gaze nystagmus in the contralateral eye
    • More frequently bilateral than unilateral
  • Demyelination of spinal cord tracts
    • Lhermitte sign: a shooting electric sensation that travels down the spine upon flexion of the neck
    • Pyramidal tract lesion: upper motor neuron weakness, spasticity, hyperreflexia, positive Babinski sign, impaired gait
    • Dorsal spinal column lesion: loss of vibration and fine-touch sensation, numbness, paresthesias, sensory ataxia usually involving the trunk or one or more limbs
    • Neuropathic pain
    • Absent abdominal reflex
  • Cerebellar involvement: poor postural control, imbalance, gait dysfunction, Charcot neurological triad of scanning speech, nystagmus, and intention tremors
  • Transverse myelitis
    • Asymmetric paraplegia, unilateral sensory loss, bladder dysfunction
    • Partial transverse myelitis is a common early manifestation of MS, causing asymmetric neurologic dysfunction below the lesion.
  • Cranial nerve palsies: diplopia, facial palsy, trigeminal neuralgia (can be bilateral)
    • Trigeminal neuralgia (TN) typically manifests unilaterally.
    • Bilateral TN should raise concern for MS, especially in younger patients.
  • Autonomic dysfunction: bowel and bladder neurogenic disorders (e.g., urinary incontinence), impaired sexual function
  • Changes in mental state: depression, emotional changes, memory deficits, impaired concentration
  • Uhthoff phenomenon: a reversible exacerbation of neurological symptoms following an increase in body temperature, e.g., physical exertion, a warm bath, or fever
    • Impulse conduction is dependent on temperature. An increase in body temperature presumably worsens impulse conduction in demyelinated nerves.

Tip

MS is a chronic condition that typically manifests in a relapsing-remitting form characterized by episodic CNS dysfunction (exacerbations) with at least partial recovery between episodes.


Diagnostics

  • Diagnosis of MS depends on a combination of clinical findings (e.g., optic neuritis, Lhermitte sign, sensory abnormalities, cerebellar signs), imaging, and laboratory results.
  • The McDonald Criteria for both DIT and DIS must both be met to confirm a diagnosis of MS:
    • Dissemination in time (DIT): the appearance of new CNS lesions over time that can be confirmed clinically, with imaging, or with CSF analysis
    • Dissemination in space (DIS): the presence of lesions in different regions of the CNS that can be confirmed clinically or in MRI

Imaging

  • MRI: Multiple sclerotic plaques (most commonly found in the periventricular white matter) with finger-like radial extensions (Dawson fingers) related to demyelination and reactive gliosisPasted image 20231231095808.pngPasted image 20231231095812.pngThere are extensive demyelinating lesions (plaques) bilaterally, appearing as hyperintensities in the periventricular white matter (green overlay). The finger-like radial extensions of these lesions are called “Dawson fingers.”

Additional studies

  • CSF examination
    • Oligoclonal bands
      • Oligoclonal bands manifest due to increased production of multiple nonspecific IgG sub-fractions in the CSF, which are caused by intrathecal inflammation.L39066.jpg
    • Other common findings: moderate lymphocytic pleocytosis, increased myelin basic protein

Tip

The presence of multiple oligoclonal bands in CSF and their absence in the blood is highly suggestive of MS.


Treatment

  • Alemtuzumab
    • A monoclonal antibody against the superficial antigen CD52; found on the surface of lymphocytes and monocytes
    • Depletes B and T lymphocytes
    • See 单抗记忆